Each patch is formulated to deliver 2 mg of BPC-157, consistent with the third-party test results, which confirmed 95.5% chromatographic purity, exceeding the 95% threshold that is widely recognized across the peptide industry as the analytical benchmark for high-purity grade peptide products, and a quantified dose of 2.02 mg of BPC-157 per patch
Consult a licensed medical provider before beginning any peptide treatment
PRP (Platelet-Rich Plasma) for Skin & Hair The ghk-cu vs prp debate centers on accessibility, mechanism, and invasiveness
Requires provider consultation and prescription
Once reconstituted for experiments, storage follows standard laboratory peptide protocols
Cognitive Decline and Neurodegenerative Conditions Cognitive decline and neurodegenerative conditions show substantial preclinical evidence across multiple pathologies: Stroke models: BPC-157 given during reperfusion counteracted neuronal damage and produced full functional recovery in spatial memory, motor coordination, and balance tests Parkinsons models: MPTP-induced models showed reduced motor symptoms (tremor, rigidity, akinesia), protection of nigrostriatal dopaminergic neurons, and near-complete prevention of mortality Multiple sclerosis models: Cuprizone-induced demyelination resulted in significantly less brain damage and reduced clinical abnormalities when BPC-157 was given in drinking water or intragastrically Traumatic brain injury: Falling weight model studies demonstrated reduced hemorrhage, decreased brain lacerations and edema, and improved early outcomes These diverse models share common mechanisms
